AVI BioPharma to Present Data for RNA-Based Influenza Drug Candidates at 2010 Chemical and Biological Defense Science and Techno
November 11 2010 - 2:00PM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, today announced the presentation of data from the
Company's influenza program at the 2010 Chemical and Biological
Defense Science and Technology Conference in Orlando, Fla.
Patrick Iversen, Ph.D., Senior Vice President of Research and
Innovation at AVI, will present during the poster session titled
"Pathogen-Directed Therapeutics," at 6 p.m. EST on Monday, Nov. 15.
The presentation, T20-028, is titled "Rapid Response Therapeutic
for Pandemic (H1N1-SOIV) and Seasonal Influenza." The presentation
will feature preclinical data evaluating the rapid response
capabilities of AVI's influenza program.
The presentation will be posted on the AVI BioPharma Web site in
the "Our Programs" section after its session is completed.
AVI-7100 is AVI's lead therapeutic candidate for influenza virus
infections. The investigational drug candidate employs AVI's
patented PMOplus™ technology that selectively introduces positive
charges to its phosphorodiamidate morpholino oligomer (PMO)
backbone to improve selective interaction between the drug and its
target.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
novel RNA-based therapeutics for rare and infectious diseases, as
well as other select disease targets. Applying pioneering
technologies developed and optimized by AVI, the Company is able to
target a broad range of diseases and disorders through distinct
RNA-based mechanisms of action. Unlike other RNA-based approaches,
AVI's technologies can be used to directly target both messenger
RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either
down-regulate (inhibit) or up-regulate (promote) the expression of
targeted genes or proteins. By leveraging a highly differentiated
RNA antisense-based technology platform, AVI has built a pipeline
of potentially transformative therapeutic agents, including one in
the clinical development stage for the treatment of Duchenne
muscular dystrophy.
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024